Cargando…
Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies
The Coronavirus disease 2019 (COVID-19) pandemic has represented an unprecedented challenge for humankind from health, economic, and social viewpoints. In February 2020, Italy was the first western country to be deeply hit by the pandemic and suffered the highest case/fatality rate among western cou...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465958/ https://www.ncbi.nlm.nih.gov/pubmed/34572349 http://dx.doi.org/10.3390/biomedicines9091163 |
_version_ | 1784573009156112384 |
---|---|
author | D’Amelio, Raffaele Asero, Riccardo Cassatella, Marco Antonio Laganà, Bruno Lunardi, Claudio Migliorini, Paola Nisini, Roberto Parronchi, Paola Quinti, Isabella Racanelli, Vito Senna, Gianenrico Vacca, Angelo Maggi, Enrico |
author_facet | D’Amelio, Raffaele Asero, Riccardo Cassatella, Marco Antonio Laganà, Bruno Lunardi, Claudio Migliorini, Paola Nisini, Roberto Parronchi, Paola Quinti, Isabella Racanelli, Vito Senna, Gianenrico Vacca, Angelo Maggi, Enrico |
author_sort | D’Amelio, Raffaele |
collection | PubMed |
description | The Coronavirus disease 2019 (COVID-19) pandemic has represented an unprecedented challenge for humankind from health, economic, and social viewpoints. In February 2020, Italy was the first western country to be deeply hit by the pandemic and suffered the highest case/fatality rate among western countries. Brand new anti-COVID-19 vaccines have been developed and made available in <1-year from the viral sequence publication. Patients with compromised immune systems, such as autoimmune-autoinflammatory disorders (AIAIDs), primary (PIDs) and secondary (SIDs) immunodeficiencies, have received careful attention for a long time regarding their capacity to safely respond to traditional vaccines. The Italian Immunological Societies, therefore, have promptly faced the issues of safety, immunogenicity, and efficacy/effectiveness of the innovative COVID-19 vaccines, as well as priority to vaccine access, in patients with AIADs, PIDs, and SIDs, by organizing an ad-hoc Task Force. Patients with AIADs, PIDs, and SIDs: (1) Do not present contraindications to COVID-19 vaccines if a mRNA vaccine is used and administered in a stabilized disease phase without active infection. (2) Should usually not discontinue immunosuppressive therapy, which may be modulated depending on the patient’s clinical condition. (3) When eligible, should have a priority access to vaccination. In fact, immunizing these patients may have relevant social/health consequences, since these patients, if infected, may develop chronic infection, which prolongs viral spread and facilitates the emergence of viral variants. |
format | Online Article Text |
id | pubmed-8465958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84659582021-09-27 Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies D’Amelio, Raffaele Asero, Riccardo Cassatella, Marco Antonio Laganà, Bruno Lunardi, Claudio Migliorini, Paola Nisini, Roberto Parronchi, Paola Quinti, Isabella Racanelli, Vito Senna, Gianenrico Vacca, Angelo Maggi, Enrico Biomedicines Review The Coronavirus disease 2019 (COVID-19) pandemic has represented an unprecedented challenge for humankind from health, economic, and social viewpoints. In February 2020, Italy was the first western country to be deeply hit by the pandemic and suffered the highest case/fatality rate among western countries. Brand new anti-COVID-19 vaccines have been developed and made available in <1-year from the viral sequence publication. Patients with compromised immune systems, such as autoimmune-autoinflammatory disorders (AIAIDs), primary (PIDs) and secondary (SIDs) immunodeficiencies, have received careful attention for a long time regarding their capacity to safely respond to traditional vaccines. The Italian Immunological Societies, therefore, have promptly faced the issues of safety, immunogenicity, and efficacy/effectiveness of the innovative COVID-19 vaccines, as well as priority to vaccine access, in patients with AIADs, PIDs, and SIDs, by organizing an ad-hoc Task Force. Patients with AIADs, PIDs, and SIDs: (1) Do not present contraindications to COVID-19 vaccines if a mRNA vaccine is used and administered in a stabilized disease phase without active infection. (2) Should usually not discontinue immunosuppressive therapy, which may be modulated depending on the patient’s clinical condition. (3) When eligible, should have a priority access to vaccination. In fact, immunizing these patients may have relevant social/health consequences, since these patients, if infected, may develop chronic infection, which prolongs viral spread and facilitates the emergence of viral variants. MDPI 2021-09-04 /pmc/articles/PMC8465958/ /pubmed/34572349 http://dx.doi.org/10.3390/biomedicines9091163 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review D’Amelio, Raffaele Asero, Riccardo Cassatella, Marco Antonio Laganà, Bruno Lunardi, Claudio Migliorini, Paola Nisini, Roberto Parronchi, Paola Quinti, Isabella Racanelli, Vito Senna, Gianenrico Vacca, Angelo Maggi, Enrico Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies |
title | Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies |
title_full | Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies |
title_fullStr | Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies |
title_full_unstemmed | Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies |
title_short | Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies |
title_sort | anti-covid-19 vaccination in patients with autoimmune-autoinflammatory disorders and primary/secondary immunodeficiencies: the position of the task force on behalf of the italian immunological societies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465958/ https://www.ncbi.nlm.nih.gov/pubmed/34572349 http://dx.doi.org/10.3390/biomedicines9091163 |
work_keys_str_mv | AT damelioraffaele anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT aseroriccardo anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT cassatellamarcoantonio anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT laganabruno anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT lunardiclaudio anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT migliorinipaola anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT nisiniroberto anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT parronchipaola anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT quintiisabella anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT racanellivito anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT sennagianenrico anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT vaccaangelo anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties AT maggienrico anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties |